An interventional study of Primary preventive treatment guided by CTCA and Cardiovascular risk Score in Coronary Atherosclerosis and Other Heart Disease and Cardiovascular Diseases, sponsored by Copenhagen University Hospital, Rigshospitalet. Enrolling by invitation at 2 sites in Denmark. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Coronary Artery Disease with a site in Denmark — 23 open to participants now, 44 under way, 5 of them phase 3. Coronary Artery Disease · Denmark.
Among the 184 studies in Coronary Artery Disease with a site in Denmark, this one is the 11th largest by planned enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2023, is one of 88 with no phase, reaches primary completion later than 25 of the 43 other live ones, and was the 163rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →23 of the 184 studies in Coronary Artery Disease with a site in Denmark are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Denmark, United States, France and 1 more country
Ages 12–130
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Odense University Hospital · Sites in Denmark
Ages 18+
Tina Vilsbøll · Sites in Denmark
Ages 18+
CSL Behring · Sites in Denmark, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 23 · Phase 4 15
First in 2002; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 455 across the 136 interventional studies, 329 across the 47 observational. Of the 116 that completed or were terminated, 27 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 184 have an industry lead sponsor. The 10 most frequent:
Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.
Copenhagen University Hospital, Rigshospitalet has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02973529Aarhus University Hospital SkejbyThe Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study | 2026-11 |
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT06606821Tina VilsbøllThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | 2027-03-20 |
| NCT06944509Philips Clinical & Medical Affairs GlobalRADIQAL Study (Radiation Dose and Image Quality Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 184 studies in Coronary Artery Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary angiography (CTCA) provides a patient-centered approach, which ensures optimal protection against serious cardiovascular disease.
The main question it aims to answer is:
Does preventive treatment guided by CTCA reduce the risk of heart attacks or cardiovascular death as compared to using conventional cardiovascular risk scores.
Participants will be randomized to preventive medical therapy and/or invasive intervention guided by either CTCA (intervention group) or Systematic COronary Risk Evaluation (SCORE) 2 model for cardiovascular risk prediction (control group).
The following hypothesis will be tested:
Primary hypothesis: Primary preventive treatment guided by CTCA reduces the risk of myocardial infarction and cardiovascular death compared to standard care in individuals with risk factors for cardiovascular disease.
Additional objectives that will be addressed in the trial include the impact of a CTCA guided preventive treatment strategy compared to standard care with regards to quality of life, adherence to pharmacological preventive therapy, frequency of invasive diagnostic and therapeutic cardiovascular procedures in addition to health economic assessment of cost-effectiveness.
Trial Design
The DANE-HEART Trial is an investigator-initiated, prospective, open label, parallel group, randomized controlled trial assessing the effect of a CTCA guided preventive treatment strategy. Consecutive individuals at risk of cardiovascular disease will be included and randomized 1:1 to the following strategies
Intervention group: Primary preventive treatment guided by CTCA
Control group: Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 risk assessment model according to Danish clinical guidelines.
Patient Cohort
Individuals participating in the Copenhagen General Population Study will be offered participation in the trial. A total of 8000 individuals will be included, or when 6000 individuals have been randomized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals participating in the Copenhagen General Population Study 40 years of age and older, with an estimate (eGFR) ≥30 mL/min/1.73 m2 will be offered participation in the trial.
Inclusion Criteria:
Patients must have at least one of the following cardiovascular risk factors:
Exclusion Criteria:
CTCA related factors
Known coronary heart disease or other major atherosclerotic cardiovascular disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary preventive treatment guided by CTCA
Diagnostic Test: Primary preventive treatment guided by CTCA
Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 model risk assessment according to Danish clinical guidelines.
Other: Cardiovascular risk Score
Computed tomography coronary angiography (CTCA)
Also known as: Wide volume CT
Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
Also known as: SCORE 2
Cardiovascular death or non-fatal acute myocardial infarction
A composite of cardiovascular death or non-fatal acute myocardial infarction
Time frame: 5 years
Acute myocardial infarction
Number of participants with acute myocardial infarction
Time frame: 5 years
Heart failure
Number of participants with heart failure
Time frame: 5 years
Stroke
Number of participants with stroke
Time frame: 5 years
Acute aortic event
Number of participants with acute aortic event
Time frame: 5 years
Cardiovascular Events
Number of participants who have fatal and non-fatal myocardial infarction or stroke
Time frame: 5 years
Death
Number of all-cause deaths
Time frame: 5 years
Coronary cardiovascular procedures
Number of Invasive coronary angiography and coronary revascularisation procedures
Time frame: 5 years
Aortic cardiovascular procedures
Number of percutaneous or surgical treatment of aortic disease
Time frame: 5 years
Aortic valve procedures
Number of percutaneous or surgical treatments of aortic valve disease
Time frame: 5 years
Quality of Life (EQ-5D-5L)
Instrument for Quality of life assessment: Euro Quality of Life - 5 Domain 5 Level (EQ-5D-5L). Value range: 0-100
Time frame: 6 months
Quality of Life (EQ-5D-5L)
Instrument for Quality of life assessment: Euro Quality of Life - 5 Domain 5 Level (EQ-5D-5L). Value range: 0-100
Time frame: 2 years
Prescriptions
Rates of prescription of preventative therapies
Time frame: 5 years
CTCA- incidental findings
Number of participants with incidental findings from CTCA
Time frame: Baseline
CTCA related - radiation dose
Radiation dose at baseline CTCA examination
Time frame: Baseline
Plan to share: Yes — The intention is to share anonymised data with external collaborators and scientists in according to General Data Protection Regulation rules and Danish laws and regulations.
Supporting information: Study protocol, Clinical study report
Time frame: 1 year after publication of main results
Access criteria: Requests by email in 2030
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 57 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Rigshospitalet